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either a full-length rat trkA receptor (pLEN trkA, donated by Dr. A. Ullrich,
Germany) or a truncated trkA lacking the tyrosine kinase domain. The latter
plasmid was constructed by digesting pLEN trkA with EcoRI. The 2.7-kb trkA
insert was purified by agarose gel electrophoresis and ligated overnight with an
EcoRI-digested TA vector (Invitrogen). TA-trkA was digested with Draffl.
Linkers d(5'-CTA GAC TAG TCT AGT U-3') and d(3'-ACC GAT CTG
ATC AGA TC-5') containing a SpeI site and an amber stop codon were
phosphorylated and ligated to the DraIll 4.5-kb and 2-kb fragments. These
fragments were then ligated to form plasmid TA-trkAi@. The 2.2-kb EcoRI
trkA fragment from TA-trkAi@was ligated to the EcoRI-digested pLEN vector.
The orientation of the insert for plasmid pLEN-trkAi@was confirmed using
Hindu!, PvuI, and SpeI. The molecular weight of the trkAA protein product
was predicted to be 44 kDa less than that of trkA. C6 glioma cells with 30â€”35
,i.g oflinearized plasmid were electroporated at 960 @Fdat 0.45 V with infinite
resistance. The cells were then resuspended in 10 ml of serum-supplemented
media and incubated for 48 h before selection was initiated in 300 @.tg/mlG4l8
(Life Technologies, Inc.).
Flow Cytometry. Forflow cytometricanalysis, 106cells were incubatedat
4Â°Cfor 2 h with 10 @gof either TA-I mab (murine IgG3) or an isotypic IgG3
control mab (Sigma Immunochemicals). The cells were then washed twice in
MEM and resuspended in 1 ml of PBS containing 1 j@gof FITC-labeled goat
anti-mouse antibody (Becton Dickinson). After two additional washes, cells
were fixed in 1% paraformaldehyde, and flow cytometric analysis was per
formed on a FACScan(BDIS). The fluorescence intensity of 10,000 viable
cells was measured.
RT-PCR. Poly(AY@RNA was preparedusing the QuickPrepmRNA Pu
rification kit (Pharmacia Biotech). RNA was heat denatured at 95Â°Cfor 5 mm
and then quickly chilled on ice. Reverse transcriptase buffer, deoxynucleotide
triphosphates, RNase inhibitor, and oligo(dT) (Perkin-Elmer GeneAmp RNA
PCR kit) were mmxedwith 1 j.@gof poly(A)@RNA and the reaction was carried
out in a Perkin-Elmer thermal cycler 480 using the RT program (15 mm at
42Â°Cfollowed by 5 mm at 99CCand cooling to 4aC). Oligonucleotide primers,
buffer, and Taq polymerase were then added and after initial heating of the
mixture to 95Â°Cfor 2 mmn,the PCR amplification was carried out for 35 cycles
(1 mmnat 94Â°C,1 mm at 58Â°C,and 2 mm at 72Â°C)with a final extension of
10 mm at 72Â°C.PCR products then were analyzed on a 2% agarose gel and
stained for 1 h with ethidium bromide. The primer sequences for trk4 and sizes
of the predicted PCR products were: 5'-CGT CAT GGC TGC 1TF TAT
GG-3'; 5'-ACT GGC GAG AAG GAG ACA C-3', 75 bp (18). For Western
blotting, cells were extracted with NP4O-containingbuffer. Protein was nor
malized using the method of Sheffield et a!. (19), and trkA was immunopre
cipitated with TA-l mab (ascites, 1:250 dilution; Ref. 20). Western blots were
then performed using polyclonal anti-trkA RTA antibody.
MTT Growth Assay Logarithmically growing cells were trypsinized and
20,000 cells in 500 pAof medium were added to a 24-well plate and then
incubated for 2 h at 37Â°C.NGF was diluted at the desired concentration in 500
@lof media, added to each well, and incubated for 4 days. Experiments were
performed in quadruplicate in DMEM/F-l2 1:1 serum-free media supple
mented with insulin and transferrin. At the end of the incubation period, 100
@.dof MiT (C18H16N5SBr; Sigma) solution (5 mg/ml in PBS) were added to
each well and incubated for 2 h at 37Â°C,after which cells were triturated in 1.1
ml of MTI' solubilization solvent solution (Sigma). Three hundred pJ of this
mixture were transferred in duplicate to a 96-well plate and the absorbance was
recorded using a ThermoMax mmcrnplatereader with a 570/650 nm filter. Cell
number was then calculated from a standard curve developed by recording
absorbances from known numbers of similar cells prepared in an identical
fashion for reading.
Soft Agarose Assay. SeaPlaque agar (1.4%; FMC Bioproducts) in water
was mixed with equal amounts of 2X serum-containing medium in a 60-mm
dish to form the lower layer. Within 1 h, the upper layer composed of equal
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ABSTRACT
We stably expressed the nerve growth factor receptor trkA or a trun
cated trkA lacking the kinase domain (trkA@) in a highly tumorigenic rat
giloma cell line, C6. Survival of rats with large mtraStriatal inocula of
C6trkA cells was significantly longer than for rats bearing C6 or C6@A
cells. Histological studies revealed that C6t@ cells were much less lava
sive than C6 or C6@'@ cells and had a greater rate of apoptosis. There
was no apparent induction of differentiation of C6 cells by trkA. There
fore, unlike what is observed in neuroblnstomas, trkA decreases tumori
genicity by modulating invasiveness and tumor cell death independent of
inducing differentialion. This novel mechanism suggests a new therapeutic
strategy for malignant gliomas.
INTRODUCTION
Malignant gliomas are highly invasive, rapidly proliferating tumors
that even with the most aggressive conventional treatments are still
associated with short survivals. Not all glial tumors are malignant,
however, and in certain instances these tumors can remain indolent for
years or be curable with surgery alone (1â€”5).Although studies address
the molecular basis of glioma malignancy, little attention has been
directed at the question of why other gliomas are benign.
In contrast, the benign character of some other neural tumors is
better understood. Patients with neuroblastomas expressing NGF3
receptor trkA have a much better prognosis than those lacking trkA
expression (6, 7). Likewise, expression of neurotrophin-3 receptor,
trkC, by medulloblastomas is associated with a favorable outcome (8).
Consistent with these clinical findings, overexpression of trkA in
neuroblastoma cell lines enhances NGF-induced differentiation both
in vitro and in vivo (9â€”il). Malignant gliomas do not express trkA
(12â€”14),but trkA expression can be induced with expression vectors.
We chose to test the effects of trkA expression on the C6 rat glioma
cell line because it has a well-characterized neuroglial phenotype and
because it rapidly and extensively invades rat brain postimplantation,
making it a useful model for human brain tumors (15â€”17).We found
that trkA-expressing C6 cells are not induced to differentiate but are
less invasive and have a higher rate of apoptosis in vivo. Furthermore,
rats bearing these cells survive significantly longer than those bearing
parental ones, demonstrating that trkA expression can decrease tumor
aggressiveness by gliomas, apparently by a novel mechanism.
MATERIALS AND METHODS
Establishment of Cell Transfectants. C6 rat glioma cells (ATCC cell
lines and hybridomas) were transfected with expression vectors encoding
Received 7/30196; accepted 12/3/96.
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volumes of cell suspension (5 X l0@cells/8 mi) and the lower layer mix was
poured at 37Â°C.NGF was added only to the upper layer. Cultures were fed
every 4â€”Sdays with 1 ml of medium with 0.05% agarose, and colonies were
counted after 2 weeks. Experiments were performed in triplicate.
Immunohistochemical Procedures. Cells on coverslips were fixed in 4%
paraformaldehyde and washed with 1% normal horse serum/0.5% Triton
X-lOO in PBS for 15 mm. The following antibodies were applied: GFAP
(Boehringer Mannheim), murine IgGl, 1:500 for 1 h; SMI3I2 (Stemberger
Monoclonals) which is directed against the heavy and medium subunits of
neurofilament, murine IgOl, 1:1000 for 1 h; and anti-trkA (TA-i), murine
lgG3, 1:250 overnight. Control isotype-matched mabs diluted in PBS at a
concentration equal to the primary antibody were always assessed concurrently
as negative controls. After incubation in primary antibody, coverslips were
rinsed three times in either 1% normal horse serum or 0.5% Triton X-l00
buffer. Biotinylated goat anti-rabbit IgG (1:200; Vector Laboratories, Inc.) was
applied for 30 mm at room temperature and rinsed for 15 mm followed by a
30-mm incubation in avidin-conjugated horseradish peroxidase (avidin-biotin
complex method; Vector Laboratories, Inc.) and developed in DAB substrate
(0.7 mg/mI DAB 2.0 mg/mI urea-H2O2,Sigma FAST tablets; Sigma) for 5
mm. Coverslips were then air dried and mounted (Permount; Fisher Chemi
cals). Samples were viewed with a Zeiss Axioskop microscope. Images from
color-positive films were digitized with a Nikon Coolscan. Brightness and
color were adjusted with Adobe Photoshop, and the color montage was
assembled with CorelDraw. The figures were printed using a KOdakColorease
PS printer on KOdakExtatherm XLS paper.
Intracranial Ineeulafions, In accordance with the University of Massa
chusetts Medical Center's guidelines concerning usage of small animals, male
Wistar-Kyoto rats (Taconic Farms, MA) weighing 200â€”250g were anesthe
tized with 70 mg/kg pentobarbital i.p. and placed in a stereotactic head holder
(David Kopf Instruments). A midline incision was made to expose the coronal,
sagittal, and lamdoidal sutures and a burr hole was made 3 mm lateral and
posterior to the bregma. Tumor cells (5 X 106)in 40 @lofMEM without serum
were loaded into a Hamilton syringe which was advanced through the drill hole
to a depth of 5 mm. The suspension was then injected over 2 mm, after which
the syringe was slowly withdrawn and the skin incision was closed with
Michel clips. Rats were then assessed daily for signs of illness (lethargy,
subconjunctival hemorrhages, weight loss, and gait impairment). For patho
logical studies, preselected animals were perfused with saline and 4%
paraformaldehyde via a transcardiac approach, after which the brains were
removed and placed in 0.2 Msodium phosphate buffer containing 30% sucrose.
Forty-pm sections were cut on a frozen microtome. Tumor extent was initially
assessed by staining sections cut through the needle tract with 1%cresyl violet
acetate solution (pH 3.8) for 30 to 60 s. Histochemical studies were then
performed in an identical manner to the in vitro samples (see above). For nestin
staining, a murine IgOl mab (PharMingen) was used. Images were processed
and prepared as described above.
Assessment of Proliferation and Apoptosls One p.g/ml murine anti
proliferating cell nuclear antigen mab (Oncogene Science) was applied over
night at 4Â°Cto sections permeabilized with 0.1% Triton X-lOO,after which
slides were washed three times in PBS and slides were developed with a
Vector avidin-biotin kit. To assess the extent of apoptosis, an ApoTag detec
tion kit (Oncor) was utilized. Forty-sm sections were hydrated in PBS and
treated with 20 pg/mi proteinase K for 15 mm at room temperature. After three
washes in distilled H2O, sections were equilibrated in PBS for 10 mm and then
endogenous peroxidases were quenched with 1% H2O2in methanol. After two
PBS washes, sections were incubated with equlibrationbuffer for 1 mm
followed by a 30-mm incubation with terminal deoxynucleotidyl transferase at
37Â°C,and the reaction was terminated with stop solution for 10 mm. After
three washes in PBS, sections were incubated with anti-digoxygenin peroxi
dare for 30 nun, washed three times in PBS, and developed with the peroxidase
reaction using a Sigma DAB substrate kit.
RESULTS
C6 glioma cells, like human glioma lines, do not express trkA
(12â€”14).We transfected C6 cells with expression vectors encoding
either a full-length rat irk receptor (C6@@) or a truncated trk receptor
which expresses the extracellular and transmembrane domains but not
the intracellular signaling component (C6@@). Receptor expression
was documented on C6@ and C6Â°@@cells using RT-PCR, Western
blotting, and flow cytometry (Fig. 1). The experimental molecular
weight of the trkAi@ product is 95,000, in good agreement with the
prediction (96,000) from the cDNA sequence. NGF treatment of
C6@ but not C6@@ resulted in tyrosine phosphorylation of the
trkA receptor (data not shown). Hence, the trkA receptor expressed in
C6ffl@Acells is functional, whereas that in C6@'@ cells is not. The
three C6 lines grew equally well in both serum-supplemented and
serum-free defined media. Addition of NGF to the medium did not
affect proliferation of C6 or C6@@ cells; however, even low doses
(100 pg/mi) of NGF increased the growth of C6@A cells (Fig. 2A), in
agreement with the findings of Colangelo et a!. (13). Furthermore,
C6@ colony formation in soft agarose increased in the presence of
NGF (P < 0.004; Fig. 2B). Long-term treatment (3 weeks) of C6@
cells with NGF did not result in dependence on NGF for survival.
Additionally, asjudged by immunohistochemistry, GFAP, a marker of
differentiated astrocytes, was not increased in C6@kAcells, compared
to either C6 or@ when cells were incubated in the presence of
NGF for 1 week. These cell culture experiments suggested that trkA
expression would increase the tumorigenicity of C6 cells.
Since in vitro results do not necessarily predict in vivo behavior
(21), we implanted 5 X 106 C6, C6@kA,and C6@@ cells into rat
striata. In this bioassay, rats harboring C6@A implants survived sig
nificantly longer than rats inoculated with either of the other two cell
lines (Fig. 3). No rat harboring C6 or C6@@ cells survived for 15
A. RT-PCR
B . WesternBlot
C. FlowCytometry
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Fig. I. Expression of trkA by C6 cell lines. A, RT-PCR detects 75-bp band charac
teristic of trkA for C6â€•@and C6â€•@ but not for C6. B, TrkA detected by Western
blotting. TrkA is not detected for C6 cells, but a Mr 140,000 band and a minor Mr 95,000
band are detected for C6â€•@and a M195,000 band is detected for C6â€•@.The minor M@
95,000 band for C6â€•@is commonly seen for trkA-expressing cells and is probably due
to proteolysis. C, Flow cytometric analysis of trkA expression on cell lines. 0, control
IgG3 nub (curves for all three lines superimposable). C6, trkA, and Delta represent
fluorescent cytograms for anti-trkA mab binding to C6, C6â€•@, and C6â€•@ cells,
respectively. C6 cells do not specifically bind anti-trkA mab, but both trkA lines do.
Log(fluorescence)
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tion. C6@ tumors were distinguished from both C6 and C6@
tumors by the lack of infiltration into normal tissue. In brain sections
stained with H&E, numerous infiltrating C6 and C6@ tumor cells
were detected in brain tissue (Fig. 4, Dâ€”F).In contrast, the C6@
â€”A--. C6@ tumors had a well-defined margin with very few cells in the surround
â€”.--. C6@ ing tissue. A similar pattern was observed when sections were immu
nostained for nestin, a primitive neuroepithelial cell marker which is
strongly positive in C6 cells but is expressed at very low levels in
adult brain (Ref. 22; Fig. 4, Gâ€”1).Again, we detected many nests of
infiltrating tumor cells for C6 and C6@@ but not for C6@.
The decreased invasiveness of C6'@ would explain the longer
survival of rats bearing these cells but would not explain the apparent
regression of the primary tumors in long-term survivors. For neuro
blastomas, trkA expression may lead to regressions by inducing tumor
differentiation (23). This mechanism is not applicable to C6Â°@@cells
since GFAP staining of these tumors was negative (Fig. 4, Jâ€”L).
However, while examining tumor cell differentiation, we detected
GFAP-positive cells that rimmed C6@ tumors, demarcating tumor
from surrounding brain, and having the appearance of reactive astro
cytes. Such a pattern was not seen with the other two lines in which
@::i-NGF theGFAPstainingin thesurroundingparenchymaappearedto be
â€” +NGF morediffuseanddisorganized.
Another mechanism by which trkA might effect tumor growth is by
influencing rates of tumor cell proliferation and apoptosis. No signif
icant differences in the number of positively stained cells were noted
using anti-proliferating cell nuclear antigen as a marker of prolifera
tion (data not shown). In contrast, C6@ tumors contained a greater
number of apoptotic cells than either C6 or C6@@ (Fig. 4, Mâ€”O).
Statistical analysis of 48 HPFs per tumor type revealed a significant
difference in the number of apoptotic cells visualized by terminal
deoxynucleotidyl transferase-mediated nick end labeling staining be
tween cell lines. Thus, although the mean number of cells per HPF
was 0.3 Â±0.1 and 0.5 Â±0.1 nucleilHPF for C6 and C6@k@ tumors,
respectively, this value was more than 4-fold greater (2.2 Â±0.3,
P < 3 X 10@'Â°,one-way ANOVA on ranks) for C6@. Enhanced
apoptosis might lead to slower growth or even regression of C6@
tumors.
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days postimplantation whereas 54% of the C6@-bearing rats sur
vived for longer than 42 days (P < 0.001, log rank test). Since rats
inoculated with as few as 5 X l0'@C6 cells expire within 3 weeks, this
prolonged survival after a substantial inoculation of C6@ cells
suggests a profound effect of trkA on in vivo tumor growth.
Postmortem examination of two long-term surviving rats bearing
C6@ cells revealed evidence of hydrocephalus but no obvious tu
mor, raising the possibility that C6@ cells either did not survive
implantation or regressed after implantation. To identify mechanisms
for increased survival of C6@-bearing rats, histological examination
of tumor-bearing rat brains was performed. Rats were sacrificed 11
days postinoculation, and brains were prepared for histological anal
ysis. All rats inoculated with C6 or C6@ cells had macroscopically
large invasive tumors. C6@ tumors were noted in all animals exam
med, but these tumors were smaller than those produced by C6 or
C6@@ cells. Hence, expression of trkA appears to influence tumor
growth rather than implantation.
Detailed histological examination of tumor-containing brains were
carried out to determine the effects of trkA on tumor growth. Staining
with anti-trkA (Fig. 4, A-C) confirmed that C6 tumors lack trkA, and
C6@ and C6@ cells continue to express receptor postimplanta
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Fig. 2. C6â€•@cells are NGF responsive in both MU and soft agarose assays. A, In the
MTF assay, 100 pg/mI NGF results in a doubling of C6â€•@cells, whereas both C6 and
C6â€•@@@areunresponsivetoNGFconcentrationsa 1000-foldhigher.Theresultsrepresent
theresultof fourexperiments;sinceSEMsare typically<1%, bars areundetectable.B,
In the soft agarose assay, the addition of 100 ng/ml NGF to the media significantly
increases colony fonnation of C6â€•@cells (P < 0.004, t test), but it has no effect on the
other two lines.
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Fig. 3. Survival of rats inoculated with C6 cell lines. After intrastriatal injections of
5 x l0@glioma cells, all rats harboring C6 or C6â€•@ cells were dead by day 15 (median
survival of 12 and 9 days, respectively), whereas 54% of the rats receiving C6â€•@cells
survived for longer than 42 days (P < 0.001, log rank test, C6â€•@versus both lines). This
graph represents the composite of inoculations performed on four separate occasions.
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.@
Fig. 4. Histological analyses ofbrain tumor see
tions demonstrating trkA expression, decreased in
vasiveness, and increased apoptosis for C6â€•@to
mors. Sections of brain tumors from the C6 (A, D,
a,j, andM),C6@(B,E,H,K,andN),and
C6â€•@ (C, F, 1, L, and 0) were stained with
anti-trkA mab TA-i (A-C), H&E (D-F), anti-ties
tin mab Rat 401 (PharMingen; Gâ€”l),anti-OFAP
polyclonal antibody (Boehringer Mannheim; Jâ€”L),
and terminal deoxynucleotidyl transferase-medi
aied nick end labeling staining for apoptotic dam
age to DNA (M-O). T, tumor. A-C: bar, 13 pin;
Dâ€”L:bar, 52 @sm;M-O: bar, 9 pin. Arrows in N
connoteapoptoticcells.
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trkA results from the signal-transducing kinase domain. This is not a
general effect induced by any receptor kinase because C6 cell lines
expressing epidermal growth factor receptor or platelet-derived
growth factor receptor are very invasive and result in short survivals
M
DISCUSSION
The basic finding of this study was that trkA expression modulates
the in vivo aggressiveness of a highly malignant glioma cell line.
Since trkA, but not trkA& enhances survival, the protective effect of
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of rats postimplantation (data not shown). Furthermore, the observa
tion that C6'@'@ cells produce aggressive tumors which result in short
survivals suggest that this effect does not result from an anti-trkA
immune response. In contrast to earlier studies with neuroblastoma
cells, we find that trkA exerts these effects without inducing differ
entiation of glioma cells (24).
Glioma invasiveness is an important determinant of clinical out
come; previous studies have indicated that the ability to invade either
normal tissue or artificial barriers is correlated with clinically malig
nant behavior (25). Decreased invasiveness might reflect changes in
motility or expression of matrix proteases, both of which are under
study in our laboratories. Enhanced apoptosis might also be another
mechanism for why trkA-expressing cells are less aggressive; it might
reflect an inability to receive sufficient nutrients due to lack of
infiltrative capacity or a dependence of the tumor cells on NGF for
survival. Although we have not detected increased apoptosis or a
dependence on NGF in vitro, it is possible that the C6@ cells in the
brain environment have different requirements for survival.
Could the induction of trkA represent a viable therapeutic strategy
for treating malignant gliomas? Motile invading glioma cells repre
sent an important reason why malignant gliomas recur despite visually
total resections and are a major reason underlying their grim prognosis
(26). Although much research has been directed toward the mecha
nisms that underlie glioma malignancy, there have been few studies
asking why certain glioma types are benign. In the juvenile pilocytic
astrocytoma of childhood, for example, neoplastic astrocytes remain
localized and confined, making them amenable to resection and long
term survival (1, 2, 4). Although the transformation of a malignant
glioma into a benign one might seem less attractive than total tumor
eradication, inhibition of glioma cell infiltration, perhaps through
induction of trk expression, might greatly improve patient survival.
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